EGFR and non-small cell lung carcinoma: This study represents the first discovery of novel treatment pathways for NSCLC involving panduratin A, which demonstrates mechanisms similar to those of osimertinib in inhibiting EGFR phosphorylation in cell lines harboring sensitizing EGFR mutations as well as in T790M mutant cell lines [29,49].